SSTR2 Radioligand Linker Structure for Higher Tumor Uptake
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current radiopharmaceuticals for neuroendocrine tumors (NETs) face challenges with reduced tumor uptake and increased accumulation in off-target tissues, limiting their therapeutic efficacy.
Innovation Solution
Development of a pharmaceutical compound with a specific six-membered cyclic linker structure connecting a somatostatin receptor subtype 2 (sstr2)-agonist to a radioisotope chelator, enhancing tumor uptake and reducing off-target accumulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If a chelator is coupled to the sstr2-agonist for radioisotope labeling, then the radioisotope can be bound for imaging and treatment, but the chelator negatively influences the binding of the agonist to the receptor, leading to reduced tumor uptake and higher accumulation in off-target tissues
Solution Approach 1:
The patent introduces a linker as an intermediary component between the sstr2-agonist and the chelator. This linker mediates the interaction by providing physical separation and optimizing the spatial arrangement, allowing the agonist to maintain its binding affinity to the sstr2 receptor while the chelator retains its ability to bind the radioisotope. The linker thus resolves the conflict between receptor binding and radioisotope complexation.
Solution Approach 2:
The patent segments the radiopharmaceutical into distinct functional modules: the sstr2-agonist portion for receptor targeting, the linker for structural optimization, and the chelator for radioisotope binding. This segmentation allows each component to perform its specific function independently, with the linker ensuring proper spatial and functional separation, thereby improving tumor uptake while reducing off-target accumulation.
2Quantity of substance
If the injected dose of the sstr2-radioligand is increased to improve treatment efficacy, then more tumor cells can be targeted, but the maximum acceptable absorbed dose to nontarget organs (bone marrow and kidneys) is exceeded
Solution Approach 1:
The patent changes the structural parameters of the radiopharmaceutical by introducing a linker with specific structural features (six-membered cyclic structure, preferred formulae IIa or IIb). This parameter change optimizes the pharmacokinetic properties, including tumor uptake and off-target clearance, allowing for a higher effective injected dose without exceeding the absorbed dose limits for bone marrow and kidneys.
3Reliability
If linkers are positioned between the agonist and chelator to improve binding, then the agonist-receptor interaction may be enhanced, but the compounds with linkers have not led to an overall improvement compared to unlinked variants
Solution Approach 1:
The patent applies specific parameter changes to the linker structure, including the six-membered cyclic moiety and preferred formulae (IIa or IIb), which optimize both binding affinity and pharmacokinetic properties. These specific structural parameters have been shown to improve overall response rate compared to previous linker designs and unlinked variants.
Solution Approach 2:
The patent creates a composite radiopharmaceutical structure combining the sstr2-agonist, specifically designed linker, and chelator into an optimized integrated molecule. This composite structure leverages the synergistic effects of each component, with the linker serving as a structurally optimized bridge that enhances both binding affinity and in vivo performance, leading to improved overall response rate.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new compound achieves higher tumor uptake and lower off-target accumulation, improving the therapeutic index for NETs treatment.
Implementation Method 1
Ch represents a radioisotope chelator; M represents the radioisotope
Implementation Method 2
T represents a sstr2-agonist; On NET cells, somatostatin receptors and especially the subtype 2 thereof (sstr2), are widely overexpressed
Implementation Method 3
L represents a linker comprising a moiety having a six-membered cyclic structure; the six-membered cyclic structure of the moiety that is part of the linker may provide rigidity to the linker
Data Source
AI summary
The invention is directed to a pharmaceutical compound, or a pharmaceutically acceptable salt thereof, for use in a medical treatment or diagnosis of tumors, in particular neuroendocrine tumors (NET). The compound is according to the formula Ch(M)-L-T, wherein Ch represents a radioisotope chelator; M represents the radioisotope; T represents a sstr2-agonist; L represents a linker comprising a moiety having a six-membered cyclic structure.